Skip to NavigationSkip to content

Shares in Molecular Templates surge after the announcement of Takeda collaboration

Published on 20/09/18 at 11:07am

Shares in the Texas based biotech Molecular Templates have soared after the company announced that they would be collaborating with Japanese pharma firm Takeda for the joint development of CD38-targeted Engineered Toxin Bodies (ETBs) for the treatment of patients with diseases such as multiple myeloma.

 Under the terms of the agreement, Takeda will make an upfront payment of $30 million. However the small Austin based company will be eligible to receive up to $632.5 million if commercial and regulatory milestones are met.

“This collaboration builds on Takeda’s deep history and commitment to the study of blood cancers, including multiple myeloma,” said Dr Philip Rowlands, Head, Oncology Therapeutic Area Unit at Takeda. “Throughout our research collaboration with Molecular Templates, we have seen the promise of its ETB platform for the discovery and development of new therapies. As we expand our relationship and continue to explore next-generation modalities, our hope is to bring forth new and important treatment options for patients.”

Notably the two companies have forged successful collaborations previously, with the lead development candidate resulting from a previous partnership.

As expanded upon by Dr Eric Poma, Molecular Templates’ Chief Executive and Scientific Officer “We have worked closely with Takeda’s scientific team since October 2016 to develop CD38-targeted ETBs with substantial improvements over our own internal program, MT-4019. Takeda’s expertise in multiple myeloma and strong antibody capabilities allowed us to develop CD38-targeted ETBs that, of the ones tested to date, are the most potent ETBs we have created with our platform.  We look forward to moving this program into the clinic.”

Shares in Molecular Templates surged by more than 60% on the announcement of the news, shooting up from 4.10 USD on Tuesday to 6.87 USD the following day.  

Louis Goss

Comments

Cards game are favorite to all if you want to  play hearts online then on our website you will play hearts without any pay and download.

 

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches